{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:41Z","timestamp":1792184681425,"version":"4.4.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.beem.2019.101370","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T20:16:44Z","timestamp":1576009004000},"page":"101370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":100,"title":["New insight in endocrine-related adverse events associated to immune checkpoint blockade"],"prefix":"10.1016","volume":"34","author":[{"given":"Giusy","family":"Elia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Martina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Galdiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ruffilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda","family":"Varricchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2019.101370_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14737140.2018.1417845","article-title":"Current and future immunotherapies for thyroid cancer","volume":"18","author":"Antonelli","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.beem.2019.101370_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1126\/science.7678351","article-title":"Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells","volume":"259","author":"Townsend","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.beem.2019.101370_bib3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/35069112","article-title":"Structural basis for co-stimulation by the human CTLA-4\/B7-2 complex","volume":"410","author":"Schwartz","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.beem.2019.101370_bib5","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.beem.2019.101370_bib6","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA\u20134 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.beem.2019.101370_bib7","doi-asserted-by":"crossref","first-page":"8099","DOI":"10.1073\/pnas.94.15.8099","article-title":"Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer","volume":"94","author":"Kwon","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2019.101370_bib8","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib10","series-title":"Update on the Phase III NEPTUNE trial of Imfinzi plus tremelimumab in Stage IV non-small cell lung cancer","author":"AstraZeneca","year":"2019"},{"key":"10.1016\/j.beem.2019.101370_bib11","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1073\/pnas.231486598","article-title":"PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine","volume":"98","author":"Okazaki","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2019.101370_bib12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beem.2019.101370_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.beem.2019.101370_bib15","doi-asserted-by":"crossref","first-page":"111ra120","DOI":"10.1126\/scitranslmed.3003130","article-title":"The PDL1-PD1 axis converts human TH1 cells into regulatory T cells","volume":"3","author":"Amarnath","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.beem.2019.101370_bib16","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beem.2019.101370_bib17","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib18","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-Line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib19","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beem.2019.101370_bib21","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib22","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib24","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib27","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib28","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.beem.2019.101370_bib30","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.beem.2019.101370_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12766","article-title":"Immune checkpoint inhibitors: the linchpins of modern immunotherapy","volume":"290","author":"Wilky","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.beem.2019.101370_bib32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2018","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.beem.2019.101370_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102560","article-title":"Autoimmune endocrine dysfunctions associated with cancer immunotherapies","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beem.2019.101370_bib34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","article-title":"Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups","volume":"20","author":"Andrews","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.beem.2019.101370_bib36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2017.01.001","article-title":"Second- and third-generation drugs for immuno-oncology treatment-The more the better?","volume":"74","author":"Dempke","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.beem.2019.101370_bib37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.beem.2019.101370_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib39","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nri.2017.112","article-title":"Lewin Immune checkpoint blockade in infectious diseases","volume":"18","author":"Wykes","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib40","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/infdis\/jix191","article-title":"Clinical trial of the anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy","volume":"215","author":"Gay","year":"2017","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.beem.2019.101370_bib41","first-page":"971","article-title":"Immune checkpoint blockade restores HIV-specific CD4 T cell help for NK cells","volume":"201","author":"Porichis","year":"2018","journal-title":"J\u00a0Immunol off J Am Assoc Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000358734","article-title":"Basophils: historical reflections and perspectives","volume":"100","author":"Marone","year":"2014","journal-title":"Chem Immunol Allergy"},{"issue":"3","key":"10.1016\/j.beem.2019.101370_bib43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/JLB.3MR0717-292R","article-title":"Roles of neutrophils in cancer growth and progression","volume":"103","author":"Galdiero","year":"2018","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.beem.2019.101370_bib44","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.3389\/fimmu.2018.01595","article-title":"Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184413","article-title":"Immune and inflammatory cells in thyroid cancer microenvironment","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beem.2019.101370_bib46","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-2265.2008.03415.x","article-title":"Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells","volume":"70","author":"Antonelli","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101370_bib47","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cyto.2011.04.022","article-title":"Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10","volume":"55","author":"Antonelli","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2019.101370_bib48","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/14712598.2019.1667975","article-title":"An update on immunotherapy options for urothelial cancer","volume":"19","author":"Bilgin","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.beem.2019.101370_bib49","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1586\/14737140.2015.1093418","article-title":"Nivolumab in combination with ipilimumab for the treatment of melanoma","volume":"15","author":"Somasundaram","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.beem.2019.101370_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"44","author":"Prasad","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib51","series-title":"Drugs.com. Keytruda approval history","year":"2019"},{"key":"10.1016\/j.beem.2019.101370_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib53","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: first global approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2019.101370_bib54","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/14712598.2014.942637","article-title":"Pidilizumab in the treatment of diffuse large B\u2013cell lymphoma","volume":"14","author":"Bryan","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.beem.2019.101370_bib55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/bs.ai.2015.12.005","article-title":"Combinatorial cancer immunotherapies","volume":"130","author":"Hellmann","year":"2016","journal-title":"Adv Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib56","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2019.101370_bib57","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib58","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.beem.2019.101370_bib59","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat Revd Cancer"},{"key":"10.1016\/j.beem.2019.101370_bib60","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib62","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review","volume":"10","author":"Gao","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.beem.2019.101370_bib63","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000247","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"2","author":"Varricchi","year":"2017","journal-title":"ESMO open"},{"key":"10.1016\/j.beem.2019.101370_bib64","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1161\/CIRCULATIONAHA.117.029626","article-title":"Cardiac toxicity of immune checkpoint inhibitors: cardio-oncology meets immunology","volume":"136","author":"Varricchi","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2019.101370_bib65","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11154-018-9463-2","article-title":"Thyroid disorders induced by checkpoint inhibitors","volume":"19","author":"Ferrari","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.beem.2019.101370_bib66","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2174\/0929867324666170407125017","article-title":"Immune checkpoint inhibitors and cardiac toxicity: an emerging issue","volume":"25","author":"Varricchi","year":"2018","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.beem.2019.101370_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20163934","article-title":"The immune landscape of thyroid cancer in the context of immune checkpoint inhibition","volume":"20","author":"Varricchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.beem.2019.101370_bib68","doi-asserted-by":"crossref","first-page":"E2383","DOI":"10.1073\/pnas.1603892113","article-title":"Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood","volume":"113","author":"Klocke","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2019.101370_bib69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.beem.2019.101370_bib70","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2018.02.038","article-title":"Cardiac toxicity in patients treated with immune checkpoint inhibitors: it is now time for cardio-immuno-oncology","volume":"71","author":"Tocchetti","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2019.101370_bib71","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphys.2018.00167","article-title":"Antineoplastic drug-induced cardiotoxicity: a redox perspective","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Physiol"},{"key":"10.1016\/j.beem.2019.101370_bib72","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1089\/ars.2016.6930","article-title":"From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview","volume":"30","author":"Tocchetti","year":"2019","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.beem.2019.101370_bib73","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2019.101370_bib74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","author":"Collins","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.beem.2019.101370_bib76","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jpainsymman.2018.05.015","article-title":"Immune checkpoint inhibitor toxicity review for the palliative care clinician","volume":"56","author":"Hansen","year":"2018","journal-title":"J\u00a0Pain Symptom Manag"},{"key":"10.1016\/j.beem.2019.101370_bib77","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti\u2013CTLA\u20134 antibodies: systematic review and meta\u2013analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.beem.2019.101370_bib78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MOG.0000000000000482","article-title":"Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?","volume":"34","author":"Siakavellas","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.beem.2019.101370_bib79","article-title":"The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors","volume":"7","author":"L\u00e4ubli","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.beem.2019.101370_bib80","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2013 immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2019.101370_bib81","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.101370_bib82","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib83","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.canlet.2019.04.018","article-title":"Management of related adverse events induced by immune checkpoint inhibition","volume":"456","author":"Teufel","year":"2019","journal-title":"Cancer Lett"},{"issue":"Suppl 4","key":"10.1016\/j.beem.2019.101370_bib84","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow\u2013up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.beem.2019.101370_bib86","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib87","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40618-018-0984-z","article-title":"Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)","volume":"42","author":"Ruggeri","year":"2019","journal-title":"J\u00a0Endocrinol Investig"},{"key":"10.1016\/j.beem.2019.101370_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40842-018-0073-4","article-title":"Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports","volume":"5","author":"Tan","year":"2019","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.beem.2019.101370_bib89","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101370_bib90","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor\u2013related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101370_bib91","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/BOR.0b013e3280113d1a","article-title":"Autoimmune thyroid diseases","volume":"19","author":"Caturegli","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.beem.2019.101370_bib92","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1210\/en.2011-1004","article-title":"From pituitary expansion to empty sella: disease progression in a mouse model of autoimmune hypophysitis","volume":"152","author":"Lupi","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2019.101370_bib93","doi-asserted-by":"crossref","first-page":"43492","DOI":"10.1038\/srep43492","article-title":"In situ activation of pituitary-infiltrating T lymphocytes in autoimmune hypophysitis","volume":"7","author":"Lin","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.beem.2019.101370_bib94","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"Castillero","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib95","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti\u2013CTLA\u20134 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.101370_bib96","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s12020-014-0199-9","article-title":"Ipilimumab, not just another anti\u2013cancer therapy: hypophysitis as side effect illustrated by four case\u2013reports","volume":"47","author":"Marlier","year":"2014","journal-title":"Endocrine"},{"key":"10.1016\/j.beem.2019.101370_bib97","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti\u2013cytotoxic T\u2013lymphocyte antigen\u20134","volume":"23","author":"Attia","year":"2005","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib98","first-page":"455","article-title":"Intrapatient dose escalation of anti\u2013CTLA\u20134 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.beem.2019.101370_bib99","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S1470-2045(12)70006-2","article-title":"Ipilimumab and a poxviral vaccine targeting prostate\u2013specific antigen in metastatic castration\u2013resistant prostate cancer: a phase 1 dose\u2013escalation trial","volume":"13","author":"Madan","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib100","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.beem.2019.101370_bib101","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab\u2013induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101370_bib102","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine\u2013related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2019.101370_bib103","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high\u2013dose corticosteroid treatment does not improve the outcome of ipilimumab\u2013related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.beem.2019.101370_bib104","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/DDDT.S196316","article-title":"Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.beem.2019.101370_bib105","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40261-018-0735-0","article-title":"Adverse event profiles of anti-CTLA-4 and anti-PD-1 monoclonal antibodies alone or in combination: analysis of spontaneous reports submitted to FAERS","volume":"39","author":"Ji","year":"2019","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.beem.2019.101370_bib106","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2019.101370_bib107","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101370_bib108","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2019.101370_bib109","article-title":"Thyroid dysfunction, recovery, and prognosis IN melanoma patients treated with immune checkpoint inhibitors: a retrospective review","author":"Al Mushref","year":"2019","journal-title":"Endocr Pract : Off J Am Coll Endocrinol Am Assoc Clin Endocrinololgist"},{"key":"10.1016\/j.beem.2019.101370_bib110","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib111","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1210\/jc.2014-4560","article-title":"Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies","volume":"100","author":"Orlov","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101370_bib112","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1346-8138.13028","article-title":"Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab","volume":"43","author":"Narita","year":"2016","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.beem.2019.101370_bib113","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12022-019-9579-2","article-title":"Pembrolizumab-induced thyroiditis","volume":"30","author":"Imblum","year":"2019","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2019.101370_bib114","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ijc.28973","article-title":"Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival","volume":"136","author":"De Remigis","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beem.2019.101370_bib115","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine\u2013related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beem.2019.101370_bib116","series-title":"Highlights of prescribing information","author":"Merck & Co. Inc.","year":"2019"},{"key":"10.1016\/j.beem.2019.101370_bib117","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol : Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib118","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.beem.2019.101370_bib119","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","article-title":"Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET\/CT","volume":"40","author":"Bacanovic","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.beem.2019.101370_bib120","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2019.101370_bib121","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.beem.2019.101370_bib122","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.beem.2019.101370_bib123","first-page":"49","article-title":"Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma","volume":"169","author":"Alzenaidi","year":"2017","journal-title":"J\u00a0La State Med Soc : Off Organ La State Med Soc"},{"key":"10.1016\/j.beem.2019.101370_bib124","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/imt-2017-0020","article-title":"A\u00a0case of fulminant Type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient","volume":"9","author":"Ara\u00fajo","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.beem.2019.101370_bib125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1399-0039.2003.00136.x","article-title":"Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes","volume":"62","author":"Nielsen","year":"2003","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.beem.2019.101370_bib126","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.beem.2019.101370_bib127","doi-asserted-by":"crossref","first-page":"542","DOI":"10.7326\/M15-3016","article-title":"Diagnosis and management of diabetes: synopsis of the 2016 American diabetes association standards of medical care in diabetes","volume":"164","author":"Chamberlain","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beem.2019.101370_bib128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first\u2013line treatment for advanced non\u2013small\u2013cell lung cancer (CheckMate 012): results of an open\u2013label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib129","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1507\/endocrj.EJ19-0234","article-title":"Comprehensive research on thyroid diseases associated with autoimmunity: autoimmune thyroid diseases, thyroid diseases during immune-checkpoint inhibitors therapy, and immunoglobulin-G4-associated thyroid diseases","volume":"66","author":"Inaba","year":"2019","journal-title":"Endocr J"},{"key":"10.1016\/j.beem.2019.101370_bib130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti-CTLA-4 antibodies","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beem.2019.101370_bib131","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2015-0509","article-title":"Spanish group for cancer immuno-biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events","volume":"21","author":"Gonz\u00e1lez-Rodr\u00edguez","year":"2016","journal-title":"The Oncologist"},{"key":"10.1016\/j.beem.2019.101370_bib132","doi-asserted-by":"crossref","first-page":"32318","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.beem.2019.101370_bib133","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/ERC-16-0421","article-title":"Comprehensive screening for PD-L1 expression in thyroid cancer","volume":"24","author":"Ahn","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2019.101370_bib134","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12022-018-9514-y","article-title":"PD-L1 and Ido1 are expressed in poorly differentiated thyroid carcinoma","volume":"29","author":"Rosenbaum","year":"2018","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2019.101370_bib135","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1530\/EJE-07-0649","article-title":"Association of an A\/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients","volume":"158","author":"Hayashi","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.101370_bib136","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.humimm.2009.06.016","article-title":"49A\/G and CT60 polymorphisms of the cytotoxic T-lymphocyte-associated antigen 4 gene associated with autoimmune thyroid disease","volume":"70","author":"Bicek","year":"2009","journal-title":"Hum Immunol"},{"key":"10.1016\/j.beem.2019.101370_bib137","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/thy.2013.0170","article-title":"Autoimmune thyroid disease elicited by NY-ESO-1 vaccination","volume":"24","author":"Vita","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2019.101370_bib138","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.2169\/internalmedicine.9518-17","article-title":"Fulminant type 1 diabetes mellitus accompanied by positive conversion of anti-insulin antibody after the administration of anti-CTLA-4 antibody following the discontinuation of anti-PD-1 antibody","volume":"57","author":"Shiba","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.beem.2019.101370_bib139","first-page":"203","article-title":"PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nature reviews","volume":"14","author":"Goodman","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beem.2019.101370_bib141","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune\u2013related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J\u00a0Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib142","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(18)30270-5","article-title":"Does a patient's sex predict the efficacy of cancer immunotherapy?","volume":"19","author":"Abdel-Rahman","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib143","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.beem.2019.101370_bib144","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat RevDrug Discov"},{"key":"10.1016\/j.beem.2019.101370_bib145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint\u2013blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:56:35Z","timestamp":1761497795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X19301216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":145,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1521690X19301216"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2019.101370","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insight in endocrine-related adverse events associated to immune checkpoint blockade","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2019.101370","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101370"}}